EcoDrugPlus

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSMAUG00000017082
Gene Symbol: HCN4
4 Cross references
287 Possible Orthologues:

Hypocretin Receptor 1

Ensembl ID : ENSMAUG00000011268
Gene Symbol: HCRTR1
4 Cross references
96 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSMAUG00000008463
Gene Symbol: HCRTR2
4 Cross references
201 Possible Orthologues:

Indoleamine 2,3-Dioxygenase 1

Ensembl ID : ENSMAUG00000011058
Gene Symbol: IDO1
3 Cross references
98 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSMAUG00000015014
Gene Symbol: IKBKB
4 Cross references
197 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSMAUG00000000330
Gene Symbol: IMPDH1
3 Cross references
333 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSMAUG00000006873
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSMAUG00000007862
Gene Symbol: INPP5D
1 Cross references
213 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSMAUG00000010750
Gene Symbol: IGF1R
3 Cross references
274 Possible Orthologues:

Integrin Beta 5

Ensembl ID : ENSMAUG00000012958
Gene Symbol: ITGB5
1 Cross references
210 Possible Orthologues:

Integrin Beta 6

Ensembl ID : ENSMAUG00000013668
Gene Symbol: ITGB6
1 Cross references
206 Possible Orthologues:

Integrin Subunit Alpha 2b

Ensembl ID : ENSMAUG00000022208
Gene Symbol: ITGA2B
4 Cross references
189 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).